



Markets
/
Stocks
/
nasdaq-igms
/

IGM Biosciences Inc

IGMS

View Detailed Chart

1.390USD

-0.070-4.79%

Close 04/23, 16:00（ET）Quotes delayed by 15 min

82.91MMarket Cap

LossP/E TTM



IGM Biosciences Inc

1.390

-0.070-4.79%

Company

Intraday

30m

Today

-4.79%

5 Days

+9.45%

1 Month

+16.81%

6 Months

-92.03%

Year to Date

-77.25%

1 Year

-79.41%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 7 analysts

HOLD

Current Rating

1.875

Target Price

28.42%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

556

Total

Median

Average

Company name

Ratings

Analysts

IGM Biosciences Inc

IGMS

CRISPR Therapeutics AG

CRSP

Regeneron Pharmaceuticals Inc

REGN

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Moderna Inc

MRNA

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(4)

Neutral(2)

Buy(5)

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.101

Neutral

RSI(14)

56.624

Neutral

STOCH(KDJ)(9,3,3)

86.560

Overbought

ATR(14)

0.133

High Vlolatility

CCI(14)

153.037

Buy

Williams %R

14.545

Overbought

TRIX(12,20)

-0.109

Sell

StochRSI(14)

70.030

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.308

Buy

MA10

1.232

Buy

MA20

1.201

Buy

MA50

1.277

Buy

MA100

3.299

Sell

MA200

7.831

Sell

News

More news coming soon, stay tuned...

Company

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Company codeIGMS

CompanyIGM Biosciences Inc

CEODr. Mary Beth Harler, M.D.

Websitehttps://igmbio.com/